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Abstract 
 
A phage-displayed peptide approach was used to identify ligands mimicking 
antigenic determinants of hepatitis A virus (HAV) for the first time. Bacteriophages 
displaying HAV mimotopes were isolated from a phage-display peptide library by 
affinity selection on serum antibodies from  hepatitis A patients. Selected phage-
peptides were screened  for reactivity with sera from HAV infected patients and healthy 
controls. Four cloned peptides with different sequences were identified as mimotopes of 
HAV; three of them showed similarity in their amino acid sequences with at least one of 
the VP3 and VP1 antigenic proteins of HAV. One  clone was recognised by 92% of the 
positive sera.  The phagotopes competed effectively with HAV for absorption of anti-
HAV specific antibodies in human sera, as determined by ELISA. The four phage 
clones induced neutralising anti-HAV antibodies in immunised mice. These results 
demonstrate the potential of this method to elucidate the disease related epitopes of 
HAV and to use these mimotopes in diagnostic applications or in the development of a 
mimotope-based hepatitis A vaccine without the necessity of manipulation of the virus.   
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1. Introduction  
 
Hepatitis A is an acute disease that has considerable morbidity and imposes a 
large economic burden, especially in developing countries. The etiological agent is 
Hepatitis A virus (HAV), classified in the genus Hepatovirus within the Picornaviridae 
family (Cuthbert, 2001).  
The IgG antibody response to HAV is delayed compared with IgM and IgA 
responses but frequently persists for life, providing protection against reinfection. Pre 
and post-exposure passive immunisation with human immune serum globulin is c.90% 
effective in preventing hepatitis A, so low levels of neutralizing antibody can give 
effective protection (Stapleton, 1995). 
The P1 region of HAV encodes the three major proteins of the viral capsid: VP1, 
VP2 and VP3. A fourth viral capsid protein (VP4), essential for virion formation, is not 
detected in mature viral particles. Each of the capsid proteins is cleaved from the 
precursor polyprotein by the viral protease 3C (Hollinger and Emerson, 2001). Human 
HAV strains are classified into a single serotype and four genotypes. Between each of 
these genotypes, the nucleotide sequence varies at 15-25% of base positions in the P1 
region. Despite this, there is good evidence that all human strains of HAV are closely 
related antigenically. Therefore, infection with any human strain is very likely to 
provide protection against all relevant human HAV strains (Lemon et al., 1992).  
Technical difficulties, such as the slow replication cycle and low yields of virus 
have hampered for years the detailed characterisation of the antigenic structure of HAV. 
Most of the information on the antigenic structure of HAV was obtained after the 
isolation of neutralization-escape mutants because the major neutralization epitopes of 
HAV appear to be discontinuous (Stapleton and Lemon, 1987). There is a 
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conformation-dependent immunodominant neutralization site, composed of clustered 
epitopes, which involves residues 70 and 74 of VP3 and residues 102, 171 and 176 of 
VP1. Similarly, there is another apparently distinct antigenic site represented by mutants 
at residue 221 of VP1 (Ping and Lemon, 1992). An additional and still undefined third 
antigenic site also exists because a monoclonal antibody was produced that effectively 
neutralises all escape mutants so far isolated (Lemon and Robertson, 1993). Three 
epitopes within the main VP3-VP1 site are present in 14S pentamers, while two 
additional epitopes are formed upon assembly of 14S subviral particles in the capsid 
(Stapleton et al., 1993). 
The availability of combinatorial peptide libraries has provided a powerful tool 
for selecting sequences that mimic conformational epitopes (mimotopes) either 
structurally and/or immunologically. These mimotopes can be particularly useful in a 
number of situations, including: the development of vaccines against tumors, infectious 
diseases or allergic conditions; the design of molecules that act as agonists or 
antagonists of various biologically-important molecules; and for the development of 
diagnostic assays (Partidos and Steward, 2002). 
The strategy to identify peptides that mimic disease-specific epitopes from 
phage-displayed random peptide libraries using human sera was previously established 
for the identification  of mimotopes of hepatitis B virus (Folgori et al., 1994) and 
hepatitis C virus (Prezzi et al., 1996). In the case of HAV,  the phage-display technique 
has only been used to clone monoclonal antibodies  from phage-displayed antibody 
libraries (Wan et al., 1998 and Scholfield et al., 2002). 
In this study, a phage-displayed peptide approach was used for the first time to 
identify ligands capable of mimicking antigenic determinants of hepatitis A virus that 
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could be useful in the development of a diagnostic kit or a potential antigen for vaccine 
production.  
 
2. Materials and methods  
 
 Sera and anti-HAV assay. 
 
              All the serum specimens used in this study were collected with written consent 
from the donors. Both  groups in the study were adults from Havana City, Cuba.   All 
the sera were tested by ELISA and did not have antibodies to HBsAg,  HCV or HIV.  
 Group A: Test serum specimens (n=24) were collected from outbreaks of 
hepatitis A.  Criteria for the diagnosis of acute hepatitis A included a clinical illness 
compatible with acute viral hepatitis, peak alanine aminotransferase (ALT) values at 
least 10 times normal, positive for total anti-HAV antibody (ELISA ETI-AB-HAVK-3, 
DiaSorin Ltd, Italy),   positive IgM anti-HAV antibody (ELISA ETI-HA-IgM-2, 
DiaSorin Ltd, Italy). 
 All the serum specimens from group A were positive for IgG anti-HAV using 
an in-house  anti IgG ELISA. Briefly, this  was performed in multi-well plates (Nunc 
Maxisorp F8, Life Technologies Limited, Paisley, UK), coated with 100 µl of  a 
solution 10 µg/ml of HAV antigen (Mediagnost, Germany) in 50 mM NaHCO3, pH 9.6 
overnight at 4ºC, then washed 3 times with PBS/0.05% Tween 20 v/v and blocked with 
PBS-T/3% BSA w/v for 1 h at 37ºC.  1/100 dilutions of serum samples were added (100 
µl/well) in duplicate and incubated 2 h at 37ºC,  plates were washed 3 times with PBS-
T, then incubated for 1 h at 37ºC with 100 µl/well of goat anti-human IgG/HRP  diluted 
1:5000 (Sigma - Aldrich, UK), washed and developed for 15 min. with TMB substrate 
(KPL, EU). The reaction was terminated with 0.1M H2SO4 and the absorbance at 450 
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nm recorded by an automated ELISA reader (Dinex Technologies, UK).  
Quantitation of anti-HAV antibody (IU/ml) from human sera was also 
performed using a quantitative Enzyme-Linked Fluorescent Assay (ELFA, VIDAS 
Anti-HAV Total, bioMerieux SA, France). One serum sample (AV1) collected from a 
donor immunised with HAVRIX hepatitis A vaccine (GSK, UK), was also included in 
this group. The anti-HAV antibodies detected in sera A16, A21 and A53 were of IgG 
class only and the remaining sera contained antibodies of both IgG and IgM class.  
Group B: Test serum specimens (n=23) were collected from healthy donors 
who had no previous history of viral hepatitis, nor any previous history of 
administration of immune globulin or hepatitis A vaccine. All serum specimens from 
this group were negative for total anti-HAV antibodies (ELISA ETI-AB-HAVK-3, 
DiaSorin Ltd, Italy) .   
All serum samples were stored at -200C until use. 
 
2.2.  J404 nonapeptide phage-display library 
 
The J404 bacteriophage display peptide library (PDPL)  used in this study was  
kindly donated by  Dr. Jim Burritt (Montana State University, USA, Burrit et al., 1996) 
 
2.3. Affinity Selection.  
 
             The methodology followed to identify HAV mimotopes using polyclonal sera is 
essentially similar to that described by Folgori et al. (1994), with some variations. 100 
µl of magnetic microbeads coupled to mouse anti-human IgG (MACS, Miltenyi Biotec, 
UK) were blocked overnight at 4oC in PBS/0.1% BSA w/v with gentle mixing. After 
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blocking, the magnetic microbeads were incubated overnight at 4oC with 30 µl of the 
selecting positive anti HAV serum A08 (610 IU/ml), bound to a magnetic column 
(Magnetic cell separator MiniMACS, Miltenyi Biotec, UK) and washed 4 times with 
PBS/0.1% BSA w/v /0.1% Tween 20 v/v (PBSB-T). The microbeads were released 
from the column and blocked with excess of UV-killed wild type phage M13K07 
particles for 4h at 4oC. They were then incubated with 1012 colony forming units (CFU) 
of J404 PDPL overnight at 4oC with gentle mixing, applied to the magnetic column 
again and washed 6 times with PBSB-T. After washing, bound phages were eluted with 
0.1 M glycine HCl, pH 2.2 and the eluate neutralised with 1M Tris HCl  pH 9.1. A few 
microliters of the eluted phage were removed for titering, and the remaining phage 
amplified in Escherichia coli strain TG1 cells [K12, ∆ (lac-pro), supE, thi, hsdD5/F’ 
traD36, proA+ B+, lacIq, lacZ∆M15, Hoogenboom et al., 1991] (Sambrook, J. and  
Russell, D. W, 2001).   
 
2.4. Immunoscreening in situ.  
 
Plaque lifts of phage colonies were prepared by placing nitrocellulose membrane 
discs on overlay plates containing 100 colonies approximately, for 4 h at room 
temperature (RT). The membranes were blocked with PBS/0.1% NP40 v/v/5%  non-fat 
dry milk w/v (PBSNM) for 2h at RT changing the buffer 4 times.   A second positive 
serum, A05 (242 IU/ml, 1/50 dilution in PBSNM) was pre-adsorbed with TG1 
Escherichia coli extract and UV-killed M13K07 phage for 2h at RT as described (Felici 
et al., 1996). The pre-adsorbed  serum was added to the nitrocellulose discs and 
incubated overnight at 4oC with gentle mixing, followed by 10 washes with PBS/0.1% 
NP40 v/v. The washed membranes were incubated with alkaline phosphatase 
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conjugated goat anti-human IgG (Sigma - Aldrich, UK, diluted 1:5000 in PBSNM) for 4 
h at 4oC washed and developed in NBT/BCIP (Pierce, UK) chromogen for 2-5 min. 
 
2.5. Immunoscreening by Slot-Blot.  
 
Positives clones identified by immunoscreening were picked using a Pasteur 
pipette, transferred to tubes containing 1 ml of LB broth following by an overnight 
incubation at 37ºC and centrifuged at 6000 g, 10 min at 4oC. The supernatant was then 
transferred to a new tube, incubated for 20 min at 70oC and centrifuged at 6000 g, 30 
min at 4oC. Supernatants from phage clones and M13K07 (negative control) were 
titered and their concentration adjusted to 7.5x107 CFU/ml. 50 µl of each sample was 
applied to a nitrocellulose membrane in a Slot-Blot apparatus. The membranes were 
blocked with PBSNM  for 2h at RT changing the buffer 4 times. Subsequent steps were 
as described above for immunoscreening in situ and all the clones were probed with 
three positive (A01, A02, A52) and three negative (B04, B94, B95) anti-HAV sera. 
 
2.6. Phage-ELISA.  
 
In this experiment the test sera from Group  A (24 sera)  and Group B (23 sera) 
were used individually in order to evaluate the specific reactivity of the phagotopes. 
Prior to ELISA each phage clone considered positive in the Slot–Blot was amplified and 
purified by PEG 8000/NaCl precipitation (Sambrook and Rusell, 2001). Phage clones 
and M13K07 phage (wild type control) were titred and their concentration adjusted to 
2.5x1012 CFU/ml. Multi-well plates (Nunc Maxisorp F8, Life Technologies Limited, 
Paisley, UK) were coated with 100 µl of anti-M13 monoclonal antibody (Amersham 
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Pharmacia Biotech, UK )  (10 µg/ml in 50 mM NaHCO3 pH 9.6). Plates were incubated 
overnight at 4oC then washed 3 times with PBS/0.05% Tween 20 v/v (PBS-T) and 
blocked with PBS-T/5% non-fat dry milk w/v for 1 h at 37oC.  Phage clones and wild 
type phage (as controls)  were added (100 µl/well) and incubated for 4h at RT. Plates 
were washed three times with PBS - T and test serum added (1/100, pre-adsorbed with 
TG1 Escherichia coli extract and UV-killed M13K07 phage, for 4h at RT). Plates were 
washed 4 times with PBS-T, incubated for 4 h at 37oC with 100 µl/well of goat anti-
human IgG/alkaline phosphatase conjugated (Sigma - Aldrich, UK) diluted 1:5000, 
washed and developed with p-nitrophenyl phosphate substrate. The absorbance at 405 
nm was recorded by an automated ELISA reader (Dinex Technologies, UK ). For each 
serum, average results from two independent experiments were evaluated. Values were 
considered as positive when the ratio (P/N) of absorbance of phage clones over 
absorbance of  phage M13K07 (wild type control) was > 2.1.   
 
2.7. Sequencing.  
 
An appropriate dilution of phage was plated in LB plates containing kanamycin (Sigma-
Aldrich, UK) at 75 µg/ml. Single colonies were excised and phage midipreps (QIA prep 
Spin, Miniprep KIT, USA) prepared in LB broth containing kanamycin at the same 
concentration. DNA from phages was sequenced using a geneIII-specific primer, which 
anneals ~50 nt from the 27-mer insert as described (Burrit et al., 1995). The phage-
displayed peptide sequences were aligned using the BLAST algorithm (Altschul et al, 
1990).  
 
2.8. Competitive Inhibition assay of HAV mimotopes.  
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The anti-HAV antibody concentration of  positive and negative sera was 
measured before and after adsorption with each of the four phagotopes and the wild type 
phage M13K07 using the semiquantitative competitive kit  ETI-AB-HAVK-3 (DiaSorin 
Kit, Italy). The assay was performed according to the supplier’s instructions. Four 
positive and three negative sera were assayed with and without pre-incubation with 
phages. Briefly, phage clones were incubated with the sera  (1:1, 108 CFU in 50 µl PBS 
+ 50 µl of serum) for 2 hours at 37ºC, before the measurement of antibody titers.  Free 
HAV was detected with anti-HAV / HRP conjugate. The absorbance at 450 nm was 
recorded by an automated ELISA reader (Dinex Technologies, UK). The samples were 
evaluated in triplicate and the experiment was performed twice. The anti-HAV 
concentration (mIU/ml) before and after incubation with the phage clones was 
calculated from the calibration curve of the positive control of the kit following the 
suppliers instructions (five calibrators were prepared by serially diluting the positive 
control serum 1: 2 v/v, from 80 to 5 mIU/ml). The statistical regression of this curve 
was 98%. The formula used for calculating the percentage inhibition of anti-HAV by 
the phage clones is: 
 % inhibition = 100- (100 x [ABS] / [NABS])  
where [ABS] is the antibody concentration  after absorption of the serum with phage 
and [NABS] is the antibody concentration before absorption, calculated from the 
regression curve of the calibrator of the kit.  
 
2.9. Immunisation of mice.  
 
Phages (BA1-54, BA1-56, BA1-53, BA1-46 and wild type phage M13) were 
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prepared for immunisation as described by de la Cruz et al., 1988. Phage clones were 
resuspended in PBS at a concentration of 1012 CFU/ml and injected intraperitoneally 
(0.1 ml/mouse) into  BALB/c mice (5 per group) as a 1:1 emulsion with complete 
Freund´s adjuvant (CFA) for the first immunisation and with incomplete Freund´s 
adjuvant (IFA) for booster injections,  at 0, 14 and 28 days. Animals were bled before 
each immunisation and at 42 days; sera were collected and stored at  -20ºC until 
evaluation. 
 
2.10. Evaluation of the anti-HAV response of immunised mice.  
 
The specific reactivity against HAV of the serum samples obtained from 
immunised mice at 0 and 42 days was determined by an indirect ELISA, performed in 
multi-well plates (Nunc Maxisorp F8, Life Technologies Limited, Paisley) coated with 
100 µl of HAV antigen (Mediagnost, Germany, 10 µg/ml) in 50 mM NaHCO3, pH 9.6 
overnight at 4ºC, then washed 3 times with PBS/0.05% Tween 20 v/v and blocked with 
PBS-T/3% BSA w/v for 1 h at 37ºC. 1/80 dilutions of serum samples were added (100 
µl/well) in duplicate and incubated 2 h at 37ºC. Plates were washed 3 times with PBS-T, 
then incubated for 1 h at 37ºC with 100 µl/well of goat anti-mouse IgG/HRP (Sigma - 
Aldrich, UK, diluted 1:5000), washed and developed for 15 min. with TMB substrate 
(KPL, EU). The reaction was terminated with 0.1M H2SO4 and the absorbance at 450 
nm recorded by an automated ELISA reader (Dynex Technologies, UK).  The optical 
density ratio of immune serum (day 42/day 0) was determined for each mouse 
individually. The data of each group were analyzed by the Kruskall -Wallis Test and 
Box and Whisker Plot, using the program Statgraphics Plus 5.0.                                   
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2.11. Cell culture.  
 
FRhK-4 cell line (ATCC CRL 1688, USA) was propagated in DMEM (GIBCO, 
USA) plus 10% fetal calf serum v/v (FCS) (GIBCO, USA) at 37 ºC with 5% CO2.   
 
2.12. Virus titration.  
 
HM175/18f cytopathic clone of HAV (ATCC VR-1402, USA) was grown in 
FRhK-4 cells and the titer determined in 96 well plates (TC Microwell 96F Nunc, 
Fisher Scientific, UK) with confluent monolayers of FRhK-4 cells. Eight replicate wells 
were inoculated with 50 µl of HAV (ten fold dilutions) in DMEM (GIBCO, USA).  
After one hour of viral absorption at 37ºC, 150 µl of DMEM/2% FCS v/v were added 
and incubated for seven days at 37ºC in a 5% CO2 atmosphere. The cytopathic effect 
(CPE) was assessed by microscopy and viral titer calculated by the method of Reed and 
Muench, 1938. 
 
2.13. Neutralization of HAV.  
 
Two fold dilutions of hyperimmune sera (collected at 42 days), pre-immune sera 
(negative control)  and a neutralizing monoclonal antibody against HAV (positive 
control Mab 7E7, Mediagnost, Germany, 25 µg/ml final concentration), were incubated 
with a fixed dilution of HAV (103 TCID50/ml).  Five replicates of each sample were 
inoculated in 96 well plates, seeded with FRhK-4 cells, and incubated for 1h at 37ºC.  
At the end of this period the monolayers were washed three times with PBS and 
DMEM/2% FCS v/v added. Plates were incubated for seven days at 37ºC in a 5% CO2 
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atmosphere and the cytopathic  effect (CPE) was observed daily.  The neutralization 
titres of the sera were scored as the reciprocal of the last dilution of serum that inhibited 
virus growth in more than 50% of the inoculated cell monolayers. 
 
3. Results 
 
3.1. Selection of HAV mimotopes.  
 
A bacteriophage display peptide library (PDPL) derived from M13mp18 vector 
was chosen as a source of epitopes. This is a randomised linear peptide library that 
contains 5x108 unique phage, each expressing a different nonapeptide sequence fused to 
the amino terminus of the pIII capsid protein. The J404 PDPL offers the benefits of high 
copy replicative form, large plaque formation, and a kanamycin resistance gene allows 
selection of colonies of E.coli infected by the phage (Burrit et al., 1996).  
In this study the sera were classified as group A or B according to the presence 
or absence of anti-hepatitis A antibody respectively (see Materials and Methods).  
Serum A08 from a convalescent hepatitis A patient with 610 IU/ml of anti-HAV 
antibody was chosen for affinity selection of the library.  1012 CFU/ml of J404 PDPL 
were affinity selected and 2.4x103 CFU/ml of bound phage were eluted. The first round 
of affinity selection was amplified to 1.5x1012 CFU/ml, plated and subjected to 
immunological screening in situ using A05 serum from a convalescent hepatitis A 
patient. 75 positive phage clones were identified  (50% of the colonies plated were 
positive). When sera are used as selectors, multiple selection steps do not necessarily 
favour enrichment of disease-specific versus non-specific phagotopes, as non-disease-
specific antibodies that would select irrelevant phagotopes may also be present in the 
serum (Felici et al., 1996). Hence, it is advisable to reduce the number of selection 
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rounds to a minimum (in most cases one round is enough), and probe a large number of 
selected clones by immunoscreening to identify the positives ones (Folgori et al., 1998). 
Since there was no enrichment after a second round of affinity selection (48% of 
colonies positive), the 75 selected clones from the first round of panning, were tested. 
Three positive sera (A01, A02 and A52) and three negative sera (B04, B94 and B95) 
were used for pre-screening by Slot Blot analysis of the BA1 phage clones.  
Several clones from the first round (BA1) were recognised by anti-HAV positive 
sera and not by negative sera.  Immunological screening by Slot-Blot is summarized in 
Table 1. Seven clones were identified from the seventy five selected by colony 
immunoscreening which were recognised by at least two of the positive sera and none 
of the three negative sera. Clones that gave positive reactions with at least one negative 
control serum were considered non-disease-related.  
 
3.2 Characterisation of HAV mimotopes using sera from convalescent hepatitis A 
patients.  
 
The final step of the procedure for selecting disease-specific phagotopes 
involves testing isolated clones for their reactivity with a large panel of positive and 
negative sera. This analysis was carried out by phage-ELISA, in which purified phage 
clones are tethered by an anti-phage monoclonal antibody (MAb) onto the surface of a 
multiwell plate. The Mab, which specifically recognizes the major capsid protein 
(pVIII), links the phage to the plate, leaving peptides displayed as a fusion with the pIII 
capsid protein free to interact with serum antibodies. 
Clones BA1-46, BA1-53, BA1-54 and BA1-56 did not react with any of the 23 
sera from a control population of healthy individuals (group B), thus confirming that the 
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selected phagotopes are disease-specific. Clones BA1-03, BA1-06 and BA1-51 were 
considered non-disease-related, and discarded from the study as they were recognized 
by 4.3, 56.5 and 47.8% respectively of the sera from group B (data not shown).   
The results shown in Table 2 indicated that 100% of the tested population of 
convalescent patients from group A contained antibodies able to recognise at least one 
of the selected phagotopes, phage BA1-56 was recognized by 92% of the tested sera. 
All four phagotopes were recognized by 28% of the sera, including serum AV1 from a 
vaccinated individual. The strongest reaction occurred with sera A12  and A16. The sera  
A01, A02, A05 and A08 were exhausted after the firsts round of selection and slot blot. 
We used the serum A52 as positive control of the slot blot results. The selected clones 
reacted with sera containing both IgM and IgG antibodies against HAV.  
 
3.3.Mapping the HAV mimotopes. 
 
The deduced amino acid sequences of the mimotopes shared several amino acids 
at the same positions as regions of the P1 and P3 proteins of the four human HAV 
strains: HM-175, CR326, MBB and LA. There was no similarity with the VP4 and VP2 
proteins. Comparison of the amino acid sequences of the mimotopes with the P1 region 
from strain HM-175 (Cohen et al., 1987) is shown in Fig. 1. Mimotope BA1-54 
exhibited discontinuous amino acid (aa) sequence similarity with two regions of the 
VP3 capsid protein (Fig. 1A), viz. 5 residues in the region aa 66 to 80 and 5 residues in 
region aa 117 to 123. Mimotope BA1-56 also exhibited discontinuous homology with 5 
residues of the VP3 protein in region aa 69 to 83, suggesting that BA1-54 and BA1-56 
resemble two discontinuous epitopes in the VP3 capsid protein. No similarity could be 
detected between the VP3 protein and mimotopes BA1-46 and BA1-53. Mimotopes 
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BA1-53 and BA1-56 exhibited discontinuous homology  with two regions of the VP1 
capsid protein (Fig. 1B). Mimotope BA1-53 displayed 6 residues homologous with VP1 
at positions  300 to 302, 320, 322 and 324. Mimotope BA1-56 also displayed 6 residues 
homologous with VP1 at positions 14 to 16, 221, 226 and 227.  Therefore, mimotopes 
BA1-53 and BA1-56 resemble two discontinuous epitopes in the VP1 capsid protein. 
No similarity could be detected between VP1 and mimotope BA1-54. The amino acid 
sequence of BA1-46  (SHSQLGPPVGPP) did not exhibit similarity with any viral 
protein and it had a hexameric sequence.   
 
3.4. Mimotopes compete with HAV for binding to antibodies in convalescent human 
sera. 
 
The reaction of the four mimotopes with anti-HAV antibodies is shown in  Fig. 
2 as the  percent inhibition of binding of anti–HAV serum to HAV compared with the   
unabsorbed sera.  BA1-56, BA1-54 and BA1-53 inhibited the binding of anti-HAV 
antibodies in all four sera tested , while  BA1-46 inhibited three of the anti-HAV sera.  
Inhibition by wild type phage was negligible. Inhibition of the reaction by all four 
phagotopes under study was greater that 3σ + inhibition after absorption with wild-type 
phage, depicted by the bar in Figure 2. No reaction was detected in the negative control 
sera.   
 
3.5. Immunogenicity of HAV mimotopes. 
 
  Groups of mice were immunised with the phage clones to determine whether 
they have the capacity to induce production of specific antibodies against HAV. All the 
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immunised animals developed a response against HAV by day 42.    
The Kruskall Wallis Test showed a statistically significant difference (p= 0.002) 
amongst the medians of the groups at the 95,0% confidence level.  The Box and 
Whisker Plot analysis (Figure 3) showed, that clones BA1-54 and BA1-46 induced  a 
higher response than BA1-56 and BA1-53; wild type phage induced the lowest 
response.  
 
3.6. Virus neutralisation.   
 
Hyperimmune sera obtained from mice immunised with the four mimotopes 
neutralised HAV infectivity at titers of 4 – 16, calculated as the reciprocal of the highest 
serum dilution capable of reducing  HAV (HM175/f8 strain) growth  by more than 50%. 
The positive control anti-HAV Mab (7E7) produced the same effect at 1:40 dilution 
(Table 3). In contrast, the pre-immune sera and sera from mice immunised with wild 
type phage had no virus neutralising capacity at any of the dilutions tested.  
 
4. Discussion 
 
Recent work has shown that phage-displayed peptides selected using antibodies 
raised against pathological antigens can be an important tool for both diagnosis and 
disease prevention (Delmastro et al., 1997; Enshell-Seiffers et al, 2001; Irving et al., 
2001; Zhang et al., 2001; Marston et al., 2002; Beckman et al., 2005). Such phage-
displayed peptides (mimotopes) do not necessarily have sequence homology with the 
antigen, but have sufficient conformational homology to induce high affinity antibodies 
that bind to both the mimotope and the natural antigen (Collins, 1997).  
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This approach has previously been used to identify mimotopes of hepatitis B and  
hepatitis C virus (Folgori et al., 1994; Prezzi et al., 1996) but not HAV, although 
antibody-phage libraries have been used to obtain monoclonal antibodies against HAV 
(Wan et al., 1998 and Scholfield et al., 2002). In the work described here, the 
application of a phage-peptide library for cloning and identifying peptides that resemble 
the antigenic structure of HAV epitopes has been exploited for the first time.   
HAV mimotopes were isolated by a three-step procedure: a) Affinity selection 
of the random peptide library with a positive serum from group A containing a high titer 
of anti-HAV antibody; b) Colony immunoscreening of the enriched phage population 
for epitopes also recognized by a second positive serum containing a high titer of  anti-
HAV antibodies. c) screening by Slot Blot and ELISA using panels of positive sera 
(group A) and negative sera (group B). The secondary screening by  slot blot with a 
reduced panel of sera (three positive and three negative sera)  facilitates the selection of 
clones before screening with the complete panels of sera, reducing the laborious work of 
selection  by ELISA of a large number of non-specific clones. 
Four peptides that mimic antigenic determinants of HAV with high specificity 
were identified. Both IgG and IgM isotypes have been shown to neutralize HAV 
(Lemon and Binn, 1983). The IgG response to HAV is delayed compared with the IgM 
response but is long-lived and accounts for resistance to reinfection (Cuthbert, 2001). 
The HAV mimotopes reacted well with both human IgG and IgM anti-HAV antibodies 
and there was no correlation between anti-HAV immunoglobulin isotype and 
mimotope.  
The concept of a mimotope is based on the assumption that the only essential 
criterion for effective binding of antibody to a peptide is that complementarity between 
the antigen-combining site of the antibody and the molecular surface of the binding 
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peptide is maintained in regard to both shape and charge. It follows, therefore, that any 
antibody-binding peptide deduced without recourse to sequence information should be 
defined as a mimotope, although it may not necessarily be an accurate reproduction of 
the epitope (Mattioli et al., 1995).  
Three of the selected mimotopes showed partial sequence homology with at 
least one of the most antigenic proteins of HAV known so far, viz. VP3 and VP1.       
Mimotope BA1-46 was recognised by 56% of the positive sera (Table 2). No 
sequence homology was found between this mimotope (SHSQLGPPVGPP) and any of 
the structural proteins of HAV. The sequence of this peptide  corresponded to a 
hexapeptide instead of the expected nonapeptide. For this reason, the sequencing              
was repeated three  times, always with the same result, suggesting that a mutated phage 
was selected. It had the ability to recognise the antibodies present in convalescent sera 
and to induce virus neutralising antibodies in mice. The absence of sequence similarity 
with HAV proteins could be due to it being a functional mimotope rather than a 
structural one, since a consensus peptide sequence may not resemble any known region 
of a linear protein if it mimics  a discontinuous region that exists only on the surface of 
a correctly folded protein (Burrit el al., 1995; Nauseef et al., 1995).   
Mimotope BA1-54 was also recognised by 56% of the positive sera and showed 
partial homology with two regions of the VP3 capsid protein. The VP3 (110-121) 
sequence is highly conserved among HAV strains and was described as a continuous 
epitope by Bosh et al., (1998). This  mimotope showed homology with the FDFXV 
motif of VP3 (117-121), which is implicated in the epitope structure of the VP3 (110-
121) sequence because shorter peptides such as VP3 (110-119), VP3 (110-117) and 
VP3 (110-116) and a tandem repeat of VP3 (111-116) failed to react with convalescent 
sera (Bosh et al., 1998).  Also, both BA1-54 and VP3 show evidence of a β-pleated 
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sheet structure in the region equivalent to aa 117-124.  On the other hand, the conserved 
RGD motif (aa 112-114) has been involved directly in the interaction of antibodies with 
the major antigenic loop of foot-and-mouth-disease virus (Verdager et al., 1995) and is 
necessary to induce the beta-structure of the peptide in the presence of liposomes 
(Perez, 1998). Despite some residues of homology with VP3 (110-121), it is not 
possible to conclude that BA1-54 mimics this linear epitope of the VP3 protein. BA1-54 
was also found to have partial homology with the VP3 (66-80) region, especially around 
Asp70, which is highly conserved among human HAV strains. VP3 Asp70 was identified 
by neutralization escape mutants as playing a critical role in the structure of an 
immunodominant neutralization site of HAV (Nainan , 1998; Ping et al., 1992) . As no 
crystallographic data on the structure of HAV exist, it is difficult to predict whether 
BA1-54 has a structural resemblance with these homology regions of VP3. 
Mimotope BA1-53 showed the lowest score of recognition by the positive sera 
(28%) and has discontinuous similarity with the VP1 (300-324) sequence.  
Mimotope BA1-56 was recognized by 92% of the positive sera.  This is the only 
mimotope that displays partial homology with both VP1 and VP3 proteins. It has 
homology with the SXSV motif of VP3 (69-72), and with the SVT motif of VP1 (Burrit 
et al., 1996; Folgori et al., 1994).  A synthetic peptide VP1 (11-25), including this SVT 
motif, induced anti-HAV neutralizing antibodies (Emini et al., 1985) but was not useful 
for immunodiagnosis of acute hepatitis A (Gómara, 2000). Chimaeric poliovirus 
expressing the VP1 (13-24) sequence induced a weak neutralizing response (Lemon, 
1992). BA1-56 also shows partial homology with VP1 (221-227) including Lys221. As 
in the case of Asp70,  this     residue was identified by neutralization escape mutants and 
is located in an independent neutralization site of HAV (Ping and Lemon, 1992). Taking 
into consideration the presence of IgM antibodies against HAV in most of the sera that 
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recognise BA1-56, indicating a recent infection and the homology of this mimotope  
with residues at neutralization sites, it is possible to  propose that it mimics important 
antigenic determinants of HAV and therefore has potential to be used for diagnostic 
applications.  
Since attempts to determine  the atomic structure of  HAV by x-ray 
crystallography  have been unsuccessful and  only medium resolution images were 
obtained by cryo-electron microscopy (Martin and Lemon, 2006), another element in 
the structural analysis that could be important is the evaluation of similarities in the 
physicochemical properties of non-homologous amino acid residues in the linear 
sequence. As an example, similarities in the size, polarity, net charge, or aliphatic 
character of residues between BA1-56 and segments 68 – 83 of VP3 and with region 
221-231 of VP1 (data not shown) were observed.  These physicochemical similarities 
could explain the recognition of the cloned peptides by anti-HAV antibodies, despite the 
absence of complete homology with the original protein. 
It would be interesting to perform further experiments to elucidate the functional 
significance of discontinuous similarity of one peptide with the regions of two different 
viral proteins (BA1-56) or the similarity of one peptide with two regions of the same 
protein (BA1-54 and BA1-56). Other authors have explained many aspects of cell 
signalling,  trafficking and targeting governed by interactions between globular proteins 
domains and short peptide segments; these domains often bind multiple peptides that 
share a common sequence pattern or “linear motif” (Neduva et al, 2005). 
Inhibition of the reaction of the human convalescent sera with HAV after 
absorption with the phage clones supports the hypothesis that the peptides mimic HAV 
epitopes, blocking  the reaction of serum antibodies with the virus. Differences in 
absorption of the antibodies by the different phage clones can be explained by 
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differences in the frequency of antibodies against the corresponding epitope and in the 
affinity of the antibodies for the mimotope.  Although BA1-46 has no homology to any 
viral sequence it was able to displace the virus in three of the four sera evaluated.  
If the selected peptides are able to adopt conformations similar to regions of 
viral proteins, it is predicted that they should induce an antibody response against the 
virus in vivo (Clark and March, 2004; Perea et al., 2004). Immunisation of mice with 
the selected phage-mimotopes induced production of anti-HAV antibodies in all the 
animals  by 42 days post immunization, compared with a much lower background 
response induced by the wild-type phage.  Similar results were obtained by other 
authors using different phagotopes mimicking antigens of HBV and HCV (Prezzi et al., 
1996; Delmastro, 1997). 
Comparisons of available neutralisation tests have shown significant differences 
in the sensitivity of these assays (Lemon, 1993; Lemon et al., 1997).   The  
neutralisation assay used here is similar to the HAV cytopathic inhibition assay (Beales 
et al., 1996), which is less labour intensive and simpler than RIFIT (Radio 
Immunofocus Inhibition Test). Antibodies induced in response to the mimotopes not 
only bound specifically to HAV, but also neutralised its infectivity and this correlated 
positively with their anti-HAV response measured by ELISA. Differences between the 
neutralisation titres of sera induced by different mimotopes could be due to differences 
in immunogenicity or in the affinity of the antibodies for the viral epitopes. The higher 
neutralization titer of Mab 7E7 compared with the mouse hyperimmune sera is probably 
due to its higher concentration and purity. Interestingly, the BA1- 56 sequence has three 
residues  in the same region (14-16) as a synthetic peptide of HAV VP1 (11-25) that 
induced low neutralizing titers (1/10) measured by RIFIT (Emini et al., 1985) 
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5. Conclusions 
 
The usefulness of phage display libraries for the isolation and  identification of 
peptides that mimic biologically relevant viral epitopes, as defined by their recognition 
by antibodies against the virus has been demonstrated in this paper.  The ability of the 
four mimotopes obtained to bind specifically to serum antibodies from convalescent 
patients could be used to develop a diagnostic assay for hepatitis A.  Their capacity to 
induce neutralising antibodies against HAV in mice suggests that these mimotopes have 
the potential to produce a mimotope-based vaccine against hepatitis A virus,  without 
requiring growth and manipulation of the virus, with its inherent high cost and 
biohazard risks.  
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Figure legends   
 Fig 1. Deduced amino acid sequences of the mimotopes and alignment with the P1 
region of HAV strain HM-175. 
(A) Alignment of mimotopes BA1-54 and BA1-56 with VP3 capsid protein.  
(B) Alignment of mimotopes BA1-53 and BA1-56 with VP1 capsid protein. Mimotope 
names are given on the left of their relative amino acid sequence. Partial sequences of 
each HAV capsid protein are shown underneath the mimotopes for comparison. 
Numbers refer to amino acid positions in the original capsid proteins after cleavage by 
protease 3C. Letters in bold represent residues shared between the mimotope and the 
HAV protein. Arrows show sites of neutralization-escape mutations: VP3 Asp70 and 
VP1 Lys221 (33, 34). 
 
Fig. 2. Inhibition of human anti-HAV antibodies by the four selected 
mimotopes. The antibody concentration before and after absorption with the phages was 
calculated from the regression curve of the calibrator. The inhibition of binding of anti-
HAV antibodies to HAV was calculated as: % inhibition = 100- (100 x ABS/NABS), 
where ABS is the concentration of antibodies after absorption with the phages and 
NABS is the concentration of antibodies before absorption.  M13 = wild-type phage 
M13K07.  The bar parallel to the X axis represents the average +3σ of the % inhibition 
of anti-HAV antibodies  after absorption with wild-type phage (21.7 %).   
 
Fig. 3. ELISA of the specific reactivity with HAV of sera from mice immunized with 
the four phagotopes and phage M13K07 (mice were bled on days 0 and 42, serum 
dilution used = 1/80). The results are represented in a “Box and Whisker Plot” as the 
ratio of OD values of serum from each immunized mouse at 42 days / OD values of 
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serum at day 0. The box encloses the middle 50 percent, the median is represented as a 
line and the mean is plotted as a point, inside the box. Corresponding medians are 5.2 
for BA1-56 clone, 9.6 for BA1-54 clone, 5.5 for BA1-53 clone, 8.9 for BA1-46 clone 
and 3.1 for M13K07 phage. Note that the wild type phage induced the lowest response, 
which differed statistically significantly  from the phagotopes (p = 0.002).  
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Table 1. Slot-Blot analysis of bound phage clones after first round of selection.  
Anti-HAV negative sera Anti-HAV positive sera 
Phage 
clones B04 B94 B95 A01 A02 A52 
BA1-03 +/- - - + - 3+ 
BA1-06 - - - + 3+ 3+ 
BA1-46 - +/- - 3+ 3+ +/- 
BA1-51 - - - 3+ + - 
BA1-53 - - - + + - 
BA1-54 - - +/- + 3+ +/- 
BA1-56 - - - + + + 
 (+) positive, (3+) strong positive, (+/-) border line, (-) negative 
Table(s)
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Table 2. ELISA reactivity of sera from convalescent hepatitis A to phagotopesa 
Sera BA1-46 BA1-53 BA1-54 BA1-56 
A06 1,1 1,4 2,5 1,8 
A07 1,3 2,2 1,5 1,9 
A11 1,5 1,3 1,6 2,2 
A12 3,2 4,5 6,0 9,1 
A13 1,3 1,2 1,7 2,3 
A16 3,3 5,2 9,6 12,0 
A18 2,3 1,9 2,3 3,2 
A21 1,2 1,3 1,7 2,3 
A22 1,4 1,4 1,9 2,2 
A23 3,4 2,4 4,1 5,7 
A25 3,0 1,0 2,0 3,0 
A26 1,5 1,3 2,7 2,2 
A27 3,1 3,5 5,6 5,7 
A28 3,2 1,1 1,8 2,2 
A29 3,3 4,2 4,3 5,3 
A30 3,5 2,5 3,5 3,0 
A31 2,7 1,8 2,7 2,7 
A32 2,3 1,7 3,2 3,5 
A33 4,0 2,0 2,1 3,1 
A35 1,5 1,1 1,7 2,2 
A52 1,5 1,1 2,0 2,2 
A53 1,9 1,3 1,9 2,2 
A54 2,4 1,3 1,9 3,7 
A55 1,9 2,0 2,8 2,7 
AV1 2,8 3,4 4,7 4,5 
ªShaded cells indicate positive results the of the test serum Group A.  
Values were considered as positive when the relation P/N > 2.1 in 
 reference of the wild  type phage.  
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Table 3. Neutralisation titre of hiperimmune serum/phage clone 
Phage 
clone  
Serum 
1 
Serum 
2 
Serum 
3 
Serum 
4 
average* 
BA1- 46 16 16 16 16 16 
BA1- 56 8 8 4 16 9 
BA1-53 0 0 8 8 4 
BA1-54 4 8 4 8 6 
* Reciprocal of the highest serum dilution capable of reducing  HM175/f8 strain growth 
by 50%. The preimmune sera and the antiserum of the wild type phage exhibited no 
effect. The Mab 7E7 used as a positive control showed an average of 40.  
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